Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept intravenous BAY 58-2667 in acute decompensated chronic congestive heart failure
2005-004473-14Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cinaciguat in heart failure (HF), sponsored by Bayer. Primary endpoints: Hemodynamic effects of BAY 58-2667, Subjective dyspnoea and 1 more. Started Dec 2005; status: completed.
02
Drugs
cinaciguat
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2005-004473-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004473-14.